Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Fineline Cube Apr 27, 2026
Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Fineline Cube Apr 27, 2026
Company Deals

Johnson & Johnson Acquires Atraverse Medical to Expand Cardiac Ablation Portfolio with Next-Gen Left-Heart Access Technology

Fineline Cube Apr 27, 2026
Company Deals

Star Sports Medicine Raises HKD 830 Million in Hong Kong IPO as China’s Leading Domestic Sports Medicine Provider

Fineline Cube Apr 24, 2026
Company Deals

Sisram Medical Forges Strategic Alliance for Daxxify Commercialization in China’s Long-Acting Botulinum Toxin Market

Fineline Cube Apr 24, 2026
Policy / Regulatory

NMPA Tightens Post-Marketing Requirements for Conditionally Approved Drugs in China, Mandating Four-Year Confirmatory Studies and Annual Progress Reporting

Fineline Cube Apr 27, 2026
Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Fineline Cube Apr 27, 2026
Company Drug

Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design

Fineline Cube Apr 27, 2026
Company Deals

MGI Tech Co., Ltd Partners with Human Cell Atlas Consortium to Advance Cell Mapping

Fineline Cube Nov 8, 2024

China-based gene sequencing specialist, MGI Tech Co., Ltd, (SHA: 688114) has announced a commercial collaboration...

Company

AstraZeneca Confirms Executive Vice President Leon Wang’s Detention in China

Fineline Cube Nov 8, 2024

AstraZeneca Inc., (AZ, NASDAQ: AZN), a leading UK pharmaceutical company, has provided an update to...

Company Deals

Jiangsu Kanion Pharmaceutical to Acquire Xintrum Pharmaceuticals for RMB 270 Million

Fineline Cube Nov 8, 2024

Jiangsu Kanion Pharmaceutical Co., Ltd (SHA: 600557), a China-based pharmaceutical company, has announced its intention...

Company Drug

Ascletis Pharma’s ASC47 Showcases Promising Weight Loss Results in Phase I Clinical Trial

Fineline Cube Nov 8, 2024

Ascletis Pharma Inc. (HKG: 1672), a China-based pharmaceutical company, has announced positive results from a...

Company Deals

Nuwacell Biotechnologies Secures RMB150 Million in Series B Financing for iPSC Therapies

Fineline Cube Nov 8, 2024

Nuwacell Biotechnologies Co., Ltd., a specialist in induced pluripotent stem cell (iPSC) technology based in...

Company Deals

Shanghai Henlius Biotech Partners with SVAX to Boost MENAT Region’s Access to Biological Drugs

Fineline Cube Nov 8, 2024

Shanghai Henlius Biotech Inc. (HKG: 2696), a leading Chinese biotech company, has entered into a...

Company Medical Device

Johnson & Johnson MedTech’s Varipulse Platform Receives FDA Approval for Atrial Fibrillation Treatment

Fineline Cube Nov 8, 2024

Johnson & Johnson MedTech (J&J, NYSE: JNJ) has announced that it has received marketing approval...

Company Drug

Sichuan Biokin Pharmaceutical Gets FDA Approval for Phase I Study of BL-M17D1 in Solid Tumors

Fineline Cube Nov 8, 2024

Sichuan Biokin Pharmaceutical Co., Ltd (SHA: 688506), a China-based pharmaceutical company, has announced that it...

Company Medical Device

Bayer AG Receives FDA 510(k) Clearance for MEDRAD Centargo CT Injection System

Fineline Cube Nov 8, 2024

Germany-based Bayer AG (ETR: BAYN) has announced that it has received 510(k) clearance from the...

Company Drug

Sichuan Huiyu Pharmaceutical’s HYP-6589 Receives NMPA Approval for Solid Tumor Clinical Trial

Fineline Cube Nov 8, 2024

Sichuan Huiyu Pharmaceutical Co., Ltd (SHA: 688553), a China-based pharmaceutical company, has announced that it...

Company Drug

Ascentage Pharma’s Lisaftoclax and AceLink Therapeutics’ AL01211 Receive FDA Designations

Fineline Cube Nov 8, 2024

The Center for Drug Evaluation (CDE) website has indicated that China-based Ascentage Pharma’s (HKG: 6855)...

Company Drug

AskBio’s AB-1003 Receives Rare Pediatric Disease and Orphan Drug Designations from FDA

Fineline Cube Nov 8, 2024

Asklepios BioPharmaceutical, Inc. (AskBio), a wholly owned subsidiary of Bayer AG (ETR: BAYN), has announced...

Company Deals

Teva Pharmaceutical Expands Partnerships in China’s One Health Sector with New Agreements

Fineline Cube Nov 8, 2024

Israel based Teva Pharmaceutical Industries Ltd (NYSE: TEVA) has announced new partnerships with Chinese firms...

Company Deals

Bayer’s Leap Forward: Implementing Salesforce on Alibaba Cloud for Customer Engagement

Fineline Cube Nov 8, 2024

Bayer (ETR: BAYN) has announced that its China Prescription Medicines business has fully adopted the...

Company Drug Policy / Regulatory

CDE Releases Technical Guidelines for Pilot Registration and Phased Manufacturing of ADCs

Fineline Cube Nov 8, 2024

The Center for Drug Evaluation (CDE) has issued the “Technical Requirements for Pilot Registration and...

Company Deals

Shanghai Pharmaceuticals’ MediTrust Health Partners with Eisai for Comprehensive Patient Services

Fineline Cube Nov 8, 2024

Shanghai Pharmaceuticals Holding Co., Ltd’s (HKG: 2607, SHA: 601607) subsidiary, MediTrust Health, which specializes in...

Company Deals

Boehringer Ingelheim Partners with Wuhan Union Hospital to Enhance Clinical Research and Development

Fineline Cube Nov 8, 2024

Boehringer Ingelheim, a leading German pharmaceutical company, has entered into a strategic partnership with Wuhan...

Policy / Regulatory

NHSA and MCA Boost Medical Assistance with Enhanced Information Sharing Measures

Fineline Cube Nov 8, 2024

The National Healthcare Security Administration (NHSA) and the Ministry of Civil Affairs (MCA) have jointly...

Company Deals

Hainan Haiyao Enters JV with Haikou and Xenios AG to Advance ECMO Technology

Fineline Cube Nov 8, 2024

Hainan Haiyao Co., Ltd (SHE: 000566), a prominent Chinese company, has announced the signing of...

Company Drug

Belief BioMed’s BBM-D101 Receives FDA Orphan Drug and Pediatric Rare Disease Designations for DMD

Fineline Cube Nov 7, 2024

Belief BioMed has announced that the U.S. Food and Drug Administration (FDA) has granted Orphan...

Posts pagination

1 … 261 262 263 … 657

Recent updates

  • Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets
  • Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease
  • Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback
  • China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio
  • Novartis Withdraws Pluvicto Pre-Chemotherapy mCRPC Application in EU Following CHMP Objections on PSMAfore Control Arm Design
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Beijing QL Biopharma Files HKEX IPO Prospectus with Diversified GLP-1 Portfolio Targeting Global Obesity and Metabolic Disease Markets

Company

Boehringer Ingelheim Launches Pulmonary Fibrosis Care Initiative in China with CNR News, Tencent Medipedia, and Patient Groups to Combat Underdiagnosed Fatal Lung Disease

Company Drug

Sanofi Secures CHMP Positive Opinion for Cenrifki (Tolebrutinib) in Non-Relapsing SPMS Despite FDA Complete Response Letter Setback

Company Deals

China Resources Double-Crane to Acquire Nanjing Xinbai Pharma from Boya Biological for RMB 235.5 Million, Expanding Injectables Portfolio

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.